{"url":"https://lda.senate.gov/api/v1/filings/8b856f6a-77b3-4e86-b65f-9dea1cdfd147/","filing_uuid":"8b856f6a-77b3-4e86-b65f-9dea1cdfd147","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2011,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/8b856f6a-77b3-4e86-b65f-9dea1cdfd147/print/","filing_document_content_type":"text/html","income":null,"expenses":"240000.00","expenses_method":"a","expenses_method_display":"Method A - Reporting amounts using LDA definitions only","posted_by_name":"William Franco, Senior Director, Government Affairs and Policy","dt_posted":"2011-04-20T13:07:41.897000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1401 I Street, NW, Suite 330","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":308536,"url":"https://lda.senate.gov/api/v1/registrants/308536/","house_registrant_id":38400,"name":"AMYLIN PHARMACEUTICALS","description":null,"address_1":"601 13th St. NW","address_2":"11th Floor, South","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"AMANDA POPOVITCH","contact_telephone":"+1 202-572-9012","dt_updated":"2022-04-06T16:08:19.591491-04:00"},"client":{"id":182808,"url":"https://lda.senate.gov/api/v1/clients/182808/","client_id":12,"name":"AMYLIN PHARMACEUTICALS","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-08-14"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Prevention, diagnosis and treatment of diabetes\nDiabetes issues related to implementation of provisions of Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":43673,"prefix":"mr","prefix_display":"MR.","first_name":"WILLIAM","nickname":null,"middle_name":"A","last_name":"FRANCO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":49696,"prefix":null,"prefix_display":null,"first_name":"CRAIG","nickname":null,"middle_name":null,"last_name":"BURTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"Exclusivity, damages, estoppel, post grant review and inter partes review provisions in the America Invents Act (S. 23, H.R. 1249)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":43673,"prefix":"mr","prefix_display":"MR.","first_name":"WILLIAM","nickname":null,"middle_name":"A","last_name":"FRANCO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":49696,"prefix":null,"prefix_display":null,"first_name":"CRAIG","nickname":null,"middle_name":null,"last_name":"BURTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Perscription Drug User Fee Act reauthorization\nFDA funding and agency effectiveness\nDrug importation issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":43673,"prefix":"mr","prefix_display":"MR.","first_name":"WILLIAM","nickname":null,"middle_name":"A","last_name":"FRANCO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":49696,"prefix":null,"prefix_display":null,"first_name":"CRAIG","nickname":null,"middle_name":null,"last_name":"BURTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"FDA funding and agency effectiveness","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":43673,"prefix":"mr","prefix_display":"MR.","first_name":"WILLIAM","nickname":null,"middle_name":"A","last_name":"FRANCO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":49696,"prefix":null,"prefix_display":null,"first_name":"CRAIG","nickname":null,"middle_name":null,"last_name":"BURTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}